Cite
Report of a Pilot Study on IL-13 As Prognostic Biomarker in Patients with Early Stage Lung Cancer Treated with Stereotactic Ablative Radiation Therapy.
MLA
Giaj-Levra, N., et al. “Report of a Pilot Study on IL-13 As Prognostic Biomarker in Patients with Early Stage Lung Cancer Treated with Stereotactic Ablative Radiation Therapy.” International Journal of Radiation Oncology, Biology, Physics, vol. 102, Nov. 2018, p. e683. EBSCOhost, https://doi.org/10.1016/j.ijrobp.2018.07.1842.
APA
Giaj-Levra, N., Trovo, M., Muraro, E., Fersino, S., Fiorentino, A., Mazzola, R., Ricchetti, F., Filippi, A. R., Ricardi, U., & Alongi, F. (2018). Report of a Pilot Study on IL-13 As Prognostic Biomarker in Patients with Early Stage Lung Cancer Treated with Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics, 102, e683. https://doi.org/10.1016/j.ijrobp.2018.07.1842
Chicago
Giaj-Levra, N., M. Trovo, E. Muraro, S. Fersino, A. Fiorentino, R. Mazzola, F. Ricchetti, A.R. Filippi, U. Ricardi, and F. Alongi. 2018. “Report of a Pilot Study on IL-13 As Prognostic Biomarker in Patients with Early Stage Lung Cancer Treated with Stereotactic Ablative Radiation Therapy.” International Journal of Radiation Oncology, Biology, Physics 102 (November): e683. doi:10.1016/j.ijrobp.2018.07.1842.